Tag - Robert Hazlett

Axsome Therapeutics

BTIG ups Axsome Therapeutics PT to $48 from $25

BTIG raised its price target for Axsome Therapeutics (NASDAQ:AXSM) to $48 from $25 after the company announced positive Phase 2 data for its AXS-12 drug candidate for the treatment of cataplexy and excessive daytime...


BTIG starts NextCure at buy; PT $61

BTIG initiated coverage of NextCure (NASDAQ:NXTC) with a “buy” rating and $61 price target. The stock closed at $39.84 on Nov. 25. NextCure is developing first‐in‐class medicines to treat cancer and other immune‐related...

ASLAN Pharmaceuticals

BTIG cuts ASLAN Pharma to neutral; removes PT

BTIG downgraded ASLAN Pharmaceuticals (NASDAQ:ASLN) to “neutral” from “buy” without a price target after the company posted top-line data for Varlitinib, a pan-HER inhibitor, in its Phase 3 TREETOP study in second-line...


Sign up to our weekly BioTuesdays newsletter.